NCT07472517
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07472517
Title DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | TUR | SWE | ROU | POL | NZL | NOR | NLD | LVA | ITA | IRL | HUN | GRC | GBR | FRA | FIN | EST | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG


No variant requirements are available.